There are small subgroups within each tumor type and within each molecular type, and someday, we might be able to actually pair the 2 to give patients a little bit more personalization and precision to their treatments, said Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology.
There are small subgroups within each tumor type and within each molecular type, and someday, we might be able to actually pair the 2 to give patients a little bit more personalization and precision to their treatments, said Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology.
Transcript
Looking ahead, where do you think the future of precision medicine is headed?
Where I think and where I hope, I hope collide. What I think at some point in the future is that patients are going to go in and have testing done and be evaluated. And based on a number of items, including their performance status, other underlying comorbidities, and probably a chip of all of their genetic and molecular material, is going to actually be put into a computer, which will hopefully spit out "this will be the best treatment or intervention," because it’s not all based on treatment, but also on interventions for you, whether it be surgery, radiation, some kind chemotherapy, or a targeted therapy, or immune therapy.
That being said, there’s a lot of other things that will play a role, and they will need to obviously be monitored. It won’t be like walking and hitting the computer key like you do in a grocery store. But, I think that things are going to advance based on a lot of the smaller data because not all people are alike the way we used to do studies. There are small subgroups within each tumor type and within each molecular type, and hopefully, at some day, we’ll be able to actually pair the 2 to give patients a little bit more personalization and precision to their treatments.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More